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Nemaline myopathy (NM) is a clinically and genetically heterogeneous disorder characterized by muscle weakness
and the presence of nemaline bodies (rods) in skeletal muscle. Disease-causing mutations have been reported in
five genes, each encoding a protein component of the sarcomeric thin filament. Recently, we identified mutations
in the muscle a-skeletal-actin gene (ACTA1) in a subset of patients with NM. In the present study, we evaluated
a new series of 35 patients with NM. We identified five novel missense mutations in ACTA1, which suggested that
mutations in muscle a-skeletal actin account for the disease in ∼15% of patients with NM. The mutations appeared
de novo and represent new dominant mutations. One proband subsequently had two affected children, a result
consistent with autosomal dominant transmission. The seven patients exhibited marked clinical variability, ranging
from severe congenital-onset weakness, with death from respiratory failure during the 1st year of life, to a mild
childhood-onset myopathy, with survival into adulthood. There was marked variation in both age at onset and
clinical severity in the three affected members of one family. Common pathological features included abnormal
fiber type differentiation, glycogen accumulation, myofibrillar disruption, and “whorling” of actin thin filaments.
The percentage of fibers with rods did not correlate with clinical severity; however, the severe, lethal phenotype
was associated with both severe, generalized disorganization of sarcomeric structure and abnormal localization of
sarcomeric actin. The marked variability, in clinical phenotype, among patients with different mutations in ACTA1
suggests that both the site of the mutation and the nature of the amino acid change have differential effects on
thin-filament formation and protein-protein interactions. The intrafamilial variability suggests that a-actin genotype
is not the sole determinant of phenotype.
Introduction
Nemaline myopathy (NM) is a genetic muscle disorder
characterized clinically by muscle weakness and hypo-
tonia and pathologically by the presence of rod-shaped
structures (nemaline bodies) in muscle fibers of affected
patients. Clinically, the disorder is heterogeneous, ranging
from death, in utero, associated with fetal akinesia (Lam-
mens et al. 1997), to a mild skeletal myopathy presenting
during childhood or adulthood (North et al. 1997). The
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weakness typically affects proximal musculature, with
variable involvement of the facial, bulbar, and respiratory
muscles. Cardiac muscle is usually spared. Nemaline bod-
ies (rods) are clearly detectable at the light-microscopy
(LM) level, and, ultrastructurally, they originate from the
Z-disks of the sarcomeres. One of the main components
of rods is a-actinin 2, an actin-binding protein that lo-
calizes to the Z-disk (Blanchard et al. 1989). Other path-
ological features of NM include abnormal fiber type dif-
ferentiation and fiber atrophy and/or hypertrophy (Volpe
et al. 1982; Miike et al. 1986; North et al. 1997). In a
subset of patients with NM, mutations have been iden-
tified in five different genes—those for a-tropomyosin
slow (TPM3) (Laing et al. 1995), nebulin (NEB) (Pelin
et al. 1999), b-tropomyosin (TPM2) (Donner et al. 2000),
troponin T1 (TNNT1) (Johnston et al. 2000), and muscle
a-skeletal actin (ACTA1 [MIM 102610]) (Nowak et al.
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1999). There are additional cases of NM that do not link
to any of the five identified loci, suggesting further genetic
heterogeneity.
In 1999, we published the first identified cases of NM
due to mutations in muscle a-skeletal actin (Nowak et
al. 1999). In skeletal muscle, actin function depends on
the balance between monomeric G-actin (globular) and
filamentous F-actin, a polymer of G-actin subunits. F-
actin, together with tropomyosin, troponin, and nebul-
in, forms the thin filaments of the skeletal-muscle con-
tractile apparatus. F-actin directly interacts withmyosin
to generate contractile force (Adelstein and Eisenberg
1980).
The frequency of actin NM and the mechanism by
which mutations in ACTA1 result in the clinical and
pathological features of NM are unknown. Here we
report a new series of patients with ACTA1 mutations
who are derived from a large Australian cohort. We
define the frequency and range of clinical and patho-
logical phenotypes associated with mutations in muscle
a-skeletal actin, and we provide insights into the patho-
genetic mechanisms underlying the disease process.
Subjects and Methods
Ascertainment of Subjects
The Australian cohort of 72 patients with NM was
ascertained through records of the neurology and pa-
thology services in each state. The diagnosis of NM was
based on European Neuromuscular Centre (ENMC) cri-
teria (Wallgren-Pettersson and Laing 2000).
Mutation Analysis
DNA for ACTA1 mutation analysis was available
from 35 patients. All patients were screened for muta-
tions in ACTA1, by sequencing of PCR products am-
plified from exons 2–7 of genomic DNA. DNA samples
isolated from 100 normal individuals served as con-
trols. When available, parental DNA samples also were
screened. The methodology was per Nowak et al.
(1999), except for the use of a different reverse primer
(5RB-5′-tgcccgccgactccatacctgg- 3′) for exon 5 and a dif-
ferent forward primer (6FB-5′-ccagccctccttcatcggtgag-3′)
for exon 6, to avoid a newly identified polymorphism
present in intron 5 on ∼15% of chromosomes.
Histochemistry and Immunohistochemistry for LM
Cryostat sections (8.0 mm) were stained by means of
the modified Gomori trichrome method described by
Engel and Cunningham (1963). We performed indirect
immunofluorescence, using mouse monoclonal (mAb)
anti–skeletal slow myosin (identifies type 1 fibers) (1:
250; Chemicon International), mouse mAb anti–skeletal
fast myosin (identifies type 2 fibers) (1:200; Sigma),
mouse mAb anti–neonatal skeletal myosin (1:100; Nov-
ocastra), affinity-purified rabbit polyclonal anti–a-ac-
tinin 2 (1:500) and anti–a-actinin 3 (1:50; North and
Beggs 1996), mouse mAb anti–sarcomeric tropomyosin
(1:400; Sigma), and mouse mAb anti-nebulin (1:400;
Sigma). To determine the expression of a–skeletal ac-
tin and other actin isoforms, we used mouse mAb
anti–sarcomeric actin (1:250; Sigma), mouse mAb
anti–a-cardiac actin (1:10; American Research Prod-
ucts), mouse mAb anti–a-smooth-muscle actin (1:100;
Sigma), mouse mAb anti–b-cytoplasmic actin (1:200;
Sigma), and sheep anti–g-cytoplasmic actin (1:200; Dr.
J. C. Bulinski). Rhodamine-phalloidin was used to iden-
tify filamentous actin (1:400; Sigma). We used either
affiniPure goat anti-mouse and anti-rabbit CY3- or fluo-
roscein-conjugated secondary antibodies (1:250 and 1:
200, respectively; Jackson ImmunoResearch Laborato-
ries) and Alexa488-conjugated goat anti-mouse (1:100;
Molecular Probes) for confocal images. All studies were
repeated on at least two occasions, to confirm initial
findings. All results were compared with results for mus-
cle tissue with normal histology, from age-matched
controls.
Stained serial sections were examined under an Olym-
pus BX50 microscope, and images were recorded by
either a SPOT Colour Digital Imaging Camera or Scan-
ning Laser Confocal Microscopy (Leica SP2). Analysis
of fiber typing and fiber diameters was performed on
photographs of serial sections stained with anti–skeletal
slow and anti–skeletal fast muscle myosin heavy-chain
antibodies.
RNA Slot-Blot Analysis
RNA was isolated from 40 frozen muscle sections (5
mm), from patient 2 and from an age- and sex-matched
control. RNA was resuspended in 20 ml of DEPC-MilliQ
water, and equal volumes were loaded, in duplicate, onto
a nylon Hybond-N transfer membrane (Amersham)
(Kingston 1997). The blots were probed with [g-32P]
end-labeled oligonucleotides complementary to the 3′
UTR of the a–skeletal-actin (gaagattcgtcgtcctgagaagtc-
gcgtgctggaggtggagtgtg) and a-cardiac-actin (aataccgtca-
tcctgactggaaggtagatggagagagaaggcatc) transcripts. The
blots were stripped and rehybridized with a human b-
spectrin–specific oligonucleotide probe (ggtctctgcgcgtcc-
cgactccgccgcgcccgccagccccacctg). Levels of transcripts
were quantified by densitometric analysis (ImageQuant,
version 4.0; Molecular Dynamics).
Results
Mutation Analysis
Five different missense ACTA1 mutations were iden-
tified in the five probands (patients 1–5) (fig. 1); these
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Figure 1 Position of mutated residues in a-skeletal actin. Five different missense mutations were identified in seven patients with NM.
These mutations’ respective locations within the actin molecule are represented by a schematic model of the three-dimensional structure of actin
(Kabsch et al. 1990, p. 37 [reprinted by permission from Nature]). Patient 1 (I357L) (orange) shows lethal severe congenital; patient 2 (R183G)
(pink), lethal severe congenital; patient 3 (G268C) (yellow), childhood onset; patient 4 (I136M) (blue), typical congenital. Also represented is
the autosomal dominant family (N115S) (purple).
represent new dominant mutations, on the basis of the
absence of family history and of sequencing of genomic
DNA from both parents of patients 1–3 and from the
mother and two unaffected children of patient 5. Patients
6 and 7 inherited the missense mutation (Asn115Ser) in
ACTA1 from their mother (patient 5). All the mutations
gave rise to SSCP variants that were not found in DNA
from 100 controls, and all mutated amino acid resi-
dues were highly conserved in known actins (fig. 2)
(Sheterline et al. 1999). Prenatal diagnosis for ACTA1
mutation was performed for the family of patient 1 dur-
ing a subsequent pregnancy; neither the parents nor the
fetus carried the ACTA1 mutation identified in the
proband.
Clinical Features
Patient 1.—This female infant was born, at term, with
severe hypotonia, minimal spontaneous movements of
the arms and legs, sparse facial movements, and fractures
of both femurs. Both the parents and a 3-year-old sibling
were clinically normal. The patient failed to achieve any
motor milestones and required a gastrostomy tube for
feeding. Results of both cranial magnetic-resonance im-
aging (MRI) and echocardiography were normal. The
patient died of respiratory failure at age 6 mo.
Patient 2.—This male infant was born, at term, with
severe hypotonia, reduced muscle bulk, lack of anti-
gravity movements, and facial diplegia. Decreased fetal
movements were noted during the last few weeks of
pregnancy. Both the parents and two siblings were clin-
ically normal. The patient failed to achieve any motor
milestones and had both difficulty in swallowing and
poor respiratory effort. Results of electrocardiography,
echocardiography, and cranial MRI were normal. The
patient died of respiratory failure at age 13 mo.
Patient 3.—This male patient, the first child of healthy
parents, had no problems during the neonatal period.
At age 5 years, he presented with both inability to run
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Figure 2 Comparison of muscle a-skeletal-actin protein se-
quences in various species and in the five mutated residues in the
patients. All mutated residues in a-skeletal actin are highly conserved
across the species shown. An asterisk (*) denotes conserved amino
acid, and a dash (–) denotes a deleted amino acid. The amino acid
numbering nomenclature corresponds to that of the human muscle a-
skeletal-actin protein sequence.
and frequent falls; he had poor muscle bulk, pes cavus,
and bilateral foot drop, suggestive of a peripheral neu-
ropathy. Electromyography showed a myopathic pat-
tern, and results of nerve conduction studies were nor-
mal. The patient had no feeding or respiratory dif-
ficulties, and echocardiography showed normal cardiac
function. At the time of the present study, he was 10
years old and had slowly progressive weakness, with
involvement of proximal muscles.
Patient 4.—This male patient was weak and floppy
from birth and had feeding difficulties, with a poor suck.
Both the parents and four siblings were clinically normal.
At age 2 years, the patient walked with assistance and
had recurrent lower-respiratory-tract infections. His
weakness has been nonprogressive. At the time of the
present study, he was 45 years old and, although he had
poor muscle bulk and mild proximal weakness, was
physically active and regularly engaged in long-distance
competitive cycling; he had a weak cough and frequent
respiratory infections. Echocardiography showed nor-
mal cardiac function.
Family A.—Family A has autosomal dominant NM.
Patient 5 was the third child of clinically unaffected nor-
mal parents with no family history of neuromuscular
disease. Both the affected mother (patient 5, who was
35 years old at the time of the present study) and the
youngest child (patient 7, who was 4 years old at the
time of the present study) display clinical features char-
acteristic of typical congenital NM, with onset of feeding
difficulties, recurrent lower-respiratory-tract infections,
hypotonia, facial diplegia, and proximal weakness dur-
ing the first weeks of life, as well as delayed motor mile-
stones. At age 3 years, patient 7 underwent a sleep study,
which demonstrated mild nocturnal hypoventilation
without significant oxygen desaturation. The weakness
has been nonprogressive, with improvement in respira-
tory status over time. Because of the family history of
NM, a pediatric neurologist evaluated patient 6 (the
daughter of patient 5) at age 4 years, and no abnormality
was detected; however, beginning at age 6 years, she
exhibited mild proximal weakness, with frequent falls,
and developed progressive scoliosis requiring surgery at
age 14 years. She has a slowly progressive disease course.
At the time of the present study, she was 19 years old
and had recurrent respiratory infections with a weak
cough and was able to run only short distances. In all
family members, echocardiography showed normal car-
diac function.
LM and Electron Microscopy (EM)
Nemaline bodies were present on Gomori trichrome
stain in biopsy samples from patients 1–6 (patient 7 has
not been biopsied) (fig. 3) and were either scattered
within the cytoplasm or clustered under the sarcolemma
(fig. 3). There was marked interpatient variability in the
percentage of fibers with rods, the proportion of indi-
vidual fibers occupied by rods, and the extent of myofi-
brillar disruption in the area surrounding the rods (as
shown by EM). Rods were present in 98%–100% of
fibers in patients 1, 4, and 6, whereas patients 2, 3, and
5 had, respectively, 50%, 14%, and 35% of fibers con-
taining rods (table 1).
In general, fiber atrophy was not a dominant histo-
pathological feature. However, EM revealed dramati-
cally atrophied fibers that were not visible by LM in the
severely affected patients (i.e., patients 1 and 2) (see fig.
4). Interestingly, in patient 4 (i.e., the cyclist), 90% of
fibers were hypertrophied (mean deltoid-fiber size ∼102
mm, compared with an age-matched normalmean of∼55
mm) (Polgar et al. 1973).
In all patients, there were abnormal glycogen accu-
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Figure 3 Gomori trichrome staining of muscle-biopsy sections.
Gomori trichrome treatment results in deep-purple staining of nem-
aline bodies (indicated by arrows), which were observed in muscle-
biopsy sections from all patients. Stained sections are shown for pa-
tients 1 (severe congenital [a]), 2 (severe congenital [b]), and 6
(childhood onset [c]).
mulations at the EM level, with abundant glycogen gran-
ules free in both the sarcoplasm and intermyofibrillar
spaces of most fibers (fig. 4). By EM, we observed ul-
trastructural changes that correlated with clinical sever-
ity. In the two patients with severe congenital NM (i.e.,
patients 1 and 2), areas containing sarcomeres were dis-
ordered in appearance, and nemaline bodies occupied a
large proportion of fibers, often in areas completely de-
void of sarcomeric structural units. Patient 1 also had
occasional central nuclei and intranuclear rods. We have
observed intranuclear rods in a total of five infants with
severe congenital NM, but only patient 1 was found to
have a mutation in a-skeletal actin (authors’ unpub-
lished data). In contrast, the mildly affected patients had
fibers containing large areas of normal sarcomeric reg-
ister. Patient 6 also had many fibers with both a “moth-
eaten” appearance and “whorling” of thin filaments (fig.
4), features that we have not observed in an age-matched
disease control without an actin mutation.
Immunohistochemistry
Fiber typing.—Staining with slow myosin demon-
strated a marked type I fiber predominance (90%–
100%) in five of the six patients, with coexpression of
both slow- and fast-myosin isoforms in a subset of fibers
in patients 1, 3, and 5 (table 1). a-Actinin 3 is a Z-line
protein expressed only in type II (i.e., fast) fibers (North
and Beggs 1996). Patients 1, 3, and 4 (in whom there
was 90%–100% type I fiber predominance) showed ab-
normal expression of a-actinin 3 in type I (i.e., slow-
myosin positive) fibers and/or in a subset of fibers ex-
pressing both slow- and fast-myosin isoforms. Patients
5 and 6 did not express detectable levels of a-actinin 3,
because of homozygosity for a stop codon in exon 16
of ACTN3, present in ∼18% of the normal population
(North et al. 1999). Patient 2 had normal type II fi-
ber–restricted a-actinin 3 expression.
Actin.—Immunocytochemical staining of muscle-bi-
opsy sections from controls, by use of an anti–a-skeletal-
actin antibody (a-sr-1, which also recognizes a-cardiac
actin) demonstrated a homogenous “honeycomb” pat-
tern of staining in a meshlike network surrounding in-
dividual myofibrils. Unexpectedly, this antibody did not
give the striated staining pattern that would be expected
if it stained the sarcomeric thin filaments. To unmask
the actin epitope in thin filaments, we performed a va-
riety of staining protocols, including acetone fixation
and glutaraldehyde fixation, detergent treatment, anti-
gen unmasking by heating, and the use of high-salt buf-
fers. None of these protocols revealed a striated staining
pattern when a-sr-1 was used (data not shown). Other
laboratories doing research on muscle tissue have ob-
tained similar results with a-sr-1 (C. Sewry and H. Jung-
bluth, personal communication). Therefore, a-sr-1 ap-
pears to recognize a-skeletal actin at the periphery of
myofibrils, rather than an epitope within sarcomeric thin
filaments.
a-Sarcomeric-actin staining of muscle sections frompa-
tients 3–6 revealed a uniform honeycomb staining pattern
when a-sr-1 was used, similar to that observed in age-
matched controls (fig. 5). However, in patients 1 and 2
(who has lethal severe congenital NM), large areas of
many fibers showed a complete absence ofa-skeletal-actin
immunoreactivity, with abnormal aggregations of actin in
a disordered distribution across the fiber (fig. 5f). This
staining pattern was not observed in an age-matched pa-
tient with severe congenital NM who does not have an
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Figure 4 EM of muscle samples from patients 1 (severe congenital NM [a and b]) and 6 (childhood onset NM [c and d]). Nemaline
bodies are present in all patients and are associated with disruption of the sarcomeric register. Rods appear either as extensions of sarcomeric
Z-lines, in random array without obvious attachment to Z-lines (often in areas devoid of sarcomeres) or in large clusters localized at the
sarcolemma or intermyofibrillar spaces (d). Glycogen accumulation (long arrow in panel a) and an increase in intermyofibrillar spaces (arrow
in panel d) are common. Additional features include intranuclear rods (short arrow in panel a) and dramatically atrophied fibers (arrow in
panel b) in patient 1, as well as whorling of thin filaments in patient 6 (arrow in panel c).
actin mutation (data not shown). a-sr-1 did not stain the
rods. However, staining with phalloidin demonstrated a
striated staining pattern and also intensely stained the rod
bodies (fig. 5), suggesting that filamentous actin is a con-
stituent of rods in these patients.
Sarcomeric proteins.—In all patients, immunohisto-
chemistry using an antibody that recognizes a-actinin 2
resulted in intense striated labeling of muscle sections
and also positively stained the rod bodies (fig. 5). Double
labeling with a-actinin 2 and a-skeletal actin (fig. 5g)
demonstrated that areas devoid of sarcomeric actin in
patients 1 and 2 contained a-actinin 2–reactive stria-
tions. Immunostaining with antibodies that recognize
tropomyosin and nebulin produced intense striated la-
beling of thin filaments but did not stain rods. In patients
1 and 2, there was striking interfiber variability in the
intensity of staining, both for tropomyosin and for ne-
bulin, a feature not observed in mildly affected patients.
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Figure 5 a-Actinin 2, sarcomeric-actin, and phalloidin staining of muscle-biopsy sections from patients 1 and 6. Immunolabeling with
a-actinin 2 both demonstrated intense positive staining of Z-lines in all the patients and intensely stained the rods (arrowheads in panels e and
i). Muscle sections labeled with a sarcomeric-actin antibody reveal a meshlike honeycomb staining pattern in the control (b) and in mildly
affected patients (as shown for patient 6, in panel j). The two severely affected patients showed abnormal localization of actin, with large areas
devoid of staining (as shown for patient 1, in panel f). Double labeling with a-actinin 2 and a-skeletal actin (g) demonstrated that areas devoid
of sarcomeric actin in patients 1 and 2 contained a-actinin 2–reactive striations. Unlike the sarcomeric-actin antibody, phalloidin demonstrated
a striated staining pattern and intensely stained the rods (arrowheads in panels h and l).
Possible Compensation by Other Actin Isoforms
a-Cardiac actin is the major actin isoform expressed
in developing and regenerating skeletal muscle. We hy-
pothesized that a-cardiac actin may compensate for mu-
tant a-skeletal actin, and we sought to determine ex-
pression levels in patients with NM and in controls.
Immunostaining of muscle sections by an antibody that
specifically recognizes a-cardiac actin produced intense
striated labeling of 10%–20% of fibers in patients 1 and
2, 1%–5% of fibers in patient 3, and occasional or ab-
sent staining in patients 4–6. For patients 3–6, these
results did not differ significantly from those observed
in age-matched controls. The age-matched control for
patients 1 and 2 showed only 1%–5% of fibers staining
for a-cardiac actin. However, a-cardiac-actin staining
was positive in 10%–20% of fibers in an age-matched
patient with severe congenital NM but without an actin
mutation, suggesting that there is an increased propor-
tion of regenerative fibers as part of the severe disease
phenotype, rather than specific compensatory up-regu-
lation of a-cardiac actin (data not shown). To confirm
these results, we performed slot-blot analysis of mRNA
encoding a-skeletal actin and a-cardiac actin, in muscle-
biopsy sections from patient 2 and from an age-matched
control (fig. 6). In both samples, the a-skeletal actin:a-
cardiac actin ratio was 4–5:1 and was not suggestive of
transcriptional up-regulation of a-cardiac actin in pa-
tient 2.
To determine whether there was altered expression of
other actin isoforms in these patients, we stained muscle
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Figure 6 RNA slot-blot analysis of a-skeletal-actin and a-car-
diac-actin transcripts. RNA from patient 2 and from an age-matched
control was blotted, in duplicate, onto membranes. Membranes were
hybridized with oligonucleotide probes complementary to the 3′ UTR
of the a-skeletal-actin or a-cardiac-actin transcripts, were washed, and
then were exposed to film. The a-skeletal actin:a-cardiac actin ratio
was ∼4–5:1 in both the patient and the control, on the basis of den-
sitometric analysis. Specificity of oligonucleotide labeling was con-
firmed by an absence of hybridization to RNA isolated from blood,
and equal loading between duplicate samples was verified by reprobing
with an oligonucleotide complementary to b-spectrin.
sections with antibodies specific to a-smooth-muscle ac-
tin, b-cytoplasmic actin, and g-cytoplasmic actin.We did
not detect any significant difference between samples
from the patients and those from controls (data not
shown).
Discussion
In this study, we have identified five novel a-skeletal-actin
mutations in a series of 35 patients with NM, suggesting
that ACTA1 mutations may account for ∼15% of NM
cases. The actin mutations in the five sporadic cases rep-
resent new dominant mutations. One proband subse-
quently had two affected children, indicating a dominant
inheritance pattern. The marked variability, in clinical
phenotype, among patients with different mutations in
muscle a-skeletal actin suggests that the site of the mu-
tation and the nature of the amino acid change have dif-
ferential effects on thin-filament formation or on protein-
protein interactions. For example, patient 1 (who has
severe congenital NM) has a mutation at residue 357
(Ile357Leu), which is an active site for competitive inter-
actions with a-actinin (Mimura and Asano 1987) and
tropomyosin (Moir and Levine 1986). Patient 2 (who has
severe congenital NM) has a mutation at residue 183
(Arg183Gly), which is involved in interactions with
DNase I and in ionic interactions with other parts of actin
(Kabsch et al. 1990). This residue, Arg183Cys, also was
mutated in a patient with a similar clinical phenotypewho
was reported by Nowak et al. (1999). The family with
autosomal dominant inheritance has a mutation at po-
sition 115 (Asn115Ser), a region also implicated in a-
actinin 2 binding (Lebart et al. 1993). The variation in
both age at onset and clinical severity in this family sug-
gests that ACTA1 genotype is not the sole determinant
of phenotype and that modifying genetic loci or stochastic
factors may influence the clinical presentation.
The pathogenesis of muscle weakness and hypotonia
in patients with actin NM is unknown, although dis-
ruption of actin structure and interactions is likely to
impair myofiber contractility. The percentage of fibers
containing rods did not correlate with disease severity.
However, the proportion of fibers occupied by rods, the
size of the rod clusters, the organization of sarcomeric
actin, and the degree of myofibrillar disruption appear
to correlate with clinical severity. For example, the two
patients with the lethal severe congenital form of NM
had both markedly abnormal localization of sarcomeric
actin and generalized disorganization of sarcomeric
structure, with many of the fibers’ regions being com-
pletely devoid of ordered sarcomeric register. Numerous
fibers in the severely affected patients were almost com-
pletely occupied by rods, and there were many atro-
phied, necrotic rod-filled fibers not visible at the LM
level. In contrast, there was both minimal sarcomeric
disruption by rods and comparatively normal ultra-
structural appearance in patients with a milder phe-
notype. Accumulation of glycogen was evident in all
patients and may reflect a decrease in efficiency of en-
ergy utilization. Other features—such as abnormalities
of sarcomeric-actin staining, whorling of thin filaments
(seen in patient 6), and an excess of thin filaments (Goe-
bel et al. 1997)—may be specific to actin myopathy and
assist in guiding a mutational analysis.
Type I fiber predominance and altered expression of
fiber type–specific genes was a common histopatholog-
ical feature. Coexpression of myosin isoforms and ex-
pression of fast fiber–specific proteins, such as a-actinin
3, in fibers expressing only slow myosin suggests, as
part of the disease process, either fiber type conversion
or an abnormality in the maturation of fiber typing.
Compensatory fiber hypertrophy was a striking feature
in patient 4, who remains physically active and cycles
regularly. Although anecdotal, this observation suggests
that patients with actin NM may benefit from regular
low-impact exercise.
There was abnormal expression of tropomyosin and
nebulin in the patients with severe congenital NM. Both
proteins are closely associated with actin in the thin
filament, and it is likely that the ACTA1 mutations af-
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fect nebulin and tropomyosin distribution. Transfection
of normal and mutant cytoplasmic actin genes into
myoblasts results in isoform-specific changes in both the
expression and organization of tropomyosin (Schevzov
et al. 1993).
In striated muscle, there is coexpression of two sar-
comeric actins—a-skeletal actin and a-cardiac actin—
that are highly conserved and that, in their amino acid
sequences, differ by only four residues. Cardiac actin is
thought to be the major actin isoform present in em-
bryonic skeletal muscle, but it is rapidly replaced, dur-
ing the postnatal period, by a-skeletal actin (Collins et
al. 1997). The expression of cardiac actin in human fetal
skeletal muscle may explain why the two patients with
severe congenital NM survived to term but exhibited
both severe hypotonia and absence of antigravity move-
ments from birth. In human fetal heart, a-cardiac actin
is the prevalent isoform, whereas a-skeletal actin is pre-
dominant (∼60%) in the adult (Boheler et al. 1991).
Although mutations in cardiac actin result in dilated
cardiomyopathy (Olson et al. 1998), none of the pa-
tients with NM with identified mutations in a-skeletal
actin have clinically detectable abnormalities of cardiac-
muscle contractility (by echocardiography). Although
we cannot exclude subclinical or histological abnor-
malities of cardiac muscle, the high level of cardiovas-
cular fitness achieved by patient 4 (the competitive long-
distance cyclist) suggests that expression of wild-type
cardiac actin and the presence of one normal ACTA1
allele) may be sufficient for normal cardiac-muscle
function.
A disease phenotype resulting from a new dominant
mutation could be the result either of a functional dom-
inant-negative effect exerted by the mutant gene or of
haploinsufficiency. Mice heterozygous for a cardiac-ac-
tin knockout are indistinguishable from their wild-type
littermates, suggesting that haploinsufficiency does not
result in a disease phenotype (Kumar et al. 1997). Our
two patients with lethal severe congenital NM had ab-
normal localization of muscle a-skeletal actin, and fil-
amentous actin was present in the rods. Taken together,
these results suggest that the mutant actin isoform exerts
a dominant-negative effect, rather than causing a defi-
ciency in steady-state levels of wild-type actin.
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